Fluorescent Label Patents (Class 436/546)
  • Patent number: 6815169
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of TL-&ggr;, antibodies to TL-&ggr;, methods of screening for TL-&ggr; modulators using biologically active TL-&ggr;, and kits for screening for TL-&ggr; modulators.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 9, 2004
    Assignee: The Regents of the University of California
    Inventors: Roman Sakowicz, Lawrence S. B. Goldstein
  • Patent number: 6812036
    Abstract: A homogeneous assay for determining the deoxynivalenol (DON) content in grains uses the technique of fluorescence polarization. A grain extract is prepared by shaking a crushed grain sample with water. A mixture is prepared by combining the grain extract with a tracer and with monoclonal antibodies specific to DON. The tracer is able to bind to the monoclonal antibodies to produce a detectable change in fluorescence polarization. The tracer is prepared by conjugating DON to a suitable fluorophore. The fluorescence polarization of the mixture is measured. The DON concentration of the mixture may be calculated using a standard curve obtained by measuring the fluorescence polarization of a series of DON solutions of known concentration.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 2, 2004
    Assignee: Diachemix LLC
    Inventors: Mohammad Sarwar Nasir, Michael E. Jolley
  • Patent number: 6808939
    Abstract: Bipyridine or phenanthroline ligands presenting functional groups that prevent non-specific binding (in particular, negatively charged functional groups that are unaffected by standard conditions for conjugating biological reagents through amide bonds) are described as are luminescent metal complexes comprising these ligands. The use of luminescent ruthenium and osmium complexes comprising these ligands in electrochemiluminescence assays shows that the use of these labels can significantly reduce the amount of non-specific binding observed relative to assays carried out using reagents labeled with analogous labels that don't present functional groups that decrease non-specific binding.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 26, 2004
    Assignees: IGEN International, Inc., BioVeris Corporation
    Inventors: George B. Sigal, Howie Tjiong, Liwen Dong, Md. Athar Masood, Richard C. Titmas
  • Publication number: 20040197844
    Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.
    Type: Application
    Filed: January 29, 2004
    Publication date: October 7, 2004
    Applicant: Mayo Foundation for Medical Education and Research, a Minnesota Corporation
    Inventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz
  • Patent number: 6794496
    Abstract: The present invention provides hapten derivatives useful for the preparation of antigens, antibodies and reagents for use in immunoassays for the detection of LSD and 2-oxo-3-hydroxy LSD. In the present invention, the 2-oxy LSD nucleus is derivatized out of the indole nitrogen to form an aminoalkyl derivative. The resulting haptens can then be further modified at this functionalized position for linking to appropriate immunogenic or labeling groups to provide reagents for immunoassays having substantially equal specificity for both LSD and 2-oxo-3-hydroxy-LSD.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: September 21, 2004
    Assignee: Roche Diagnostics Corporation
    Inventors: Mitali Ghoshal, Stephen Vitone, Gerald F. Sigler, Alan J. McNally
  • Patent number: 6787325
    Abstract: Provided are novel complexes containing a crosslinked avidin, an analyzing method and analyzing reagents and kits whereby a compound to be analyzed can be quickly, conveniently and accurately analyzed while taking advantage of the avidin-biotin reaction. The complexes contain at least two homogeneous or heterogeneous biotin-introduced products and one crosslinked avidin sandwiched therebetween. In the analyzing method, the homogeneous or heterogeneous biotin-introduced products and the crosslinked avidin are used. The analyzing reagent contains the crosslinked avidin. The analyzing kit contains the crosslinked avidin and a biotinylating agent.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: September 7, 2004
    Assignees: Iatron Laboratories, Inc., Kikkoman Corporation
    Inventors: Kazuyuki Sugiyama, Nobuhiro Hoshino, Hiroki Tatsumi, Satoshi Fukuda
  • Patent number: 6780581
    Abstract: A method for the production of a product containing a quantum of bioparticles, for example bacterial cells, is provided, as are products obtained thereby. In one embodiment, the products contain a defined quantum of bioparticles, preferably presented in a viable state. Products made in accordance with the invention may be usefully put to applications where having knowledge of the number of bioparticles present may be important or at least advantageous.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: August 24, 2004
    Assignee: BTF Pty Ltd
    Inventors: Graham Vesey, Mark Gauci
  • Patent number: 6777246
    Abstract: A reagent for use in immunoassays reduces interference in particle agglutination assays. The reagent contains particles having covalently bound antibodies and a tertiary amine compound of formula (I): N(R1—X)(R2—Y)(R3—Z)  (I). The moieties R1, R2, and R3 are independently alkyl or alkyl ether. The moieties X, Y, and Z are independently —OH, —O—R4, —S—R4, —C(═O)—OH, —C(═O)—OR4, or —C(═O)—NHR4 (R4 is alkyl).
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: August 17, 2004
    Assignee: Roche Diagnostics GmbH
    Inventors: Christopher C. Lawrence, Armen B. Shanafelt
  • Patent number: 6773928
    Abstract: Compositions of matter and methods for enhancing bioassay performance are disclosed. More particularly, the composition of matter comprises a molecularly compact polymer-ligand conjugate capable of self-orienting on a surface to improve the orientation of the ligand/receptor binding domains within the bioassay at the nanoscopic level. In a preferred embodiment, the molecularly compact polymer comprises a dendrimer polymer such as a fifth generation polyamidoamine dendrimer having exterior surface hydroxyl and amine functional groups, and the ligand/receptor comprises an antibody or Fab.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: August 10, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ray Yin, H. Dupont Durst, Peter A. Emanuel, Gary L. Hagnauer
  • Patent number: 6774361
    Abstract: A novel encoding system and methods for determining the location and/or identity of a particular item or component of interest is provided. In particular, the present invention utilizes a “barcode” comprising one or more sizes of semiconductor nanocrystals (quantum dots) having characteristic spectral emissions, to either “track” the location of a particular item of interest or to identify a particular item of interest. The semiconductor nanocrystals used in the inventive “barcoding” scheme can be tuned to a desired wavelength to produce a characteristic spectral emission in narrow spectral widths, and with a symmetric, nearly Gaussian line shape, by changing the composition and size of the quantum dot. Additionally, the intensity of the emission at a particular characteristic wavelength can also be varied, thus enabling the use of binary or higher order encoding schemes.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: August 10, 2004
    Assignee: Massachusetts Institute of Technology
    Inventors: Moungi G. Bawendi, Klavs F. Jensen
  • Patent number: 6759206
    Abstract: The present invention provides systems, methods, and screens to measure receptor internalization in a single step with appropriate automation and throughput. This approach involves luminescent labeling of the receptor of interest and the automated measurement of receptor internalization to a perinuclear location.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: July 6, 2004
    Assignee: Cellomics, Inc.
    Inventors: Richard A. Rubin, Kenneth A. Giuliano, Albert H. Gough, R. Terry Dunlay
  • Patent number: 6756207
    Abstract: The present invention provides systems, methods, screens, reagents and kits for optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: June 29, 2004
    Assignee: Cellomics, Inc.
    Inventors: Kenneth A. Giuliano, Gary Bright, Keith Olson, Sarah Burroughs Tencza
  • Patent number: 6753156
    Abstract: The invention relates to a novel homogeneous method of detecting and/or determining the phosphorylating activity of a biological material towards a substrate containing tyrosine and/or serine and/or threonine, and to a kit for carrying out this method.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: June 22, 2004
    Assignee: Cis Bio International
    Inventors: Gérard Mathis, Eric Trinquet, Marc Preaudat
  • Patent number: 6753153
    Abstract: The differential expression of marker proteins in a targeted population provides a means of identifying and isolating cells. A population of cells associated with the regeneration of pancreatic islets is shown to express certain proteins, including the cell surface proteins ErbB2, ErbB3, and ErbB4; and the nuclear protein Msx-2. Populations of isolated pancreatic islet progenitor cells find use in screening assays, to characterize genes involved in islet development and regulation, and in transplantation to provide a recipient with pancreatic islet functions.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: June 22, 2004
    Assignee: The Scripps Research Institute
    Inventors: Nora Sarvetnick, Marcie Kritzik
  • Patent number: 6750034
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed D-G. The deduced amino acid sequence, and it's alignment with other well characterized serine proteases clearly indicates that it is a member of the S1 serine protease family. We have found that the protease D-G mRNA is widely expressed in several tissues throughout the body including epidermis, fibroblasts, keratinocytes, colon, small intestine, stomach, lung, kidney, bone marrow, lymph node, thymus, ovary, prostate, uterus and spinal cord. Interestingly, this protease contains a hydrophobic stretch of amino acids which is a putative transmembrane near the NH2-terminus. Thus, this serine protease is thought to be synthesized as a type II integral protein.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: June 15, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Andrew L. Darrow, Jenson (Jian-Shen) Qi, Patricia Andrade-Gordon
  • Patent number: 6747135
    Abstract: The present invention is directed to novel polypeptides, termed fluorettes, that bind with high avidity to fluorophore dyes. The peptides find use in a variety of methods and approaches involving fluorophore dyes.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: June 8, 2004
    Assignee: The Board of Trustees for the Leland Stanford Junior University
    Inventors: Garry P. Nolan, Michael N. Rozinov
  • Patent number: 6743591
    Abstract: A method for counting leukocytes which comprises liberating elastase from granulocytes contained in a specimen, adding an anti-granulocyte elastase antibody to the thus liberated elastase, measuring the antibody bonded to the elastase to thereby determine the concentration of the elastase, and then calculating therefrom the number of leukocytes contained in the specimen with the use of the ratio of the leukocyte count to the elastase concentration. This method makes it possible to conveniently and less expensively count leukocytes at a high accuracy comparable to the one established by using a conventional automatic blood cell counter, as the figure shows.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: June 1, 2004
    Assignee: Arkray, Inc.
    Inventors: Akio Okubo, Shigeki Yamada
  • Patent number: 6740257
    Abstract: Disclosed is a modular fluorescence sensor having the following general formula: Where Fl is a fluorophore, N is a nitrogen atom, Bd1 and Bd2 are independently selected binding groups, Sp is an aliphatic spacer, and An is an anchor group for attaching the sensor to solid substrates. n=1 or 2, m=1 or 2, x is an integer, and y=1 or 2. The binding groups are capable of binding an analyte molecule to form a stable 1:1 complex. In a preferred embodiment, the Bd1 is R1—B(OH)2 and Bd2 is R2—B(OH)2. R1 and R2 are aliphatic or aromatic functional groups selected independently from each other and B is a boron atom. The present invention also provides methods of synthesizing a modular fluorescence sensor and its use in labeling solid substrates.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: May 25, 2004
    Assignee: Beckman Coulter, Inc.
    Inventors: Susumu Arimori, Tony D. James
  • Patent number: 6740495
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: May 25, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung
  • Patent number: 6737279
    Abstract: The present invention provides a method of detecting a biological agent including contacting a sample with a sensor including a polymer system capable of having an alterable measurable property from the group of luminescence, anisotropy, redox potential and uv/vis absorption, the polymer system including an ionic conjugated polymer and an electronically inert polyelectrolyte having a biological agent recognition element bound thereto, the electronically inert polyelectrolyte adapted for undergoing a conformational structural change upon exposure to a biological agent having affinity for binding to the recognition element bound to the electronically inert polyelectrolyte, and, detecting the detectable change in the alterable measurable property. A chemical moiety being the reaction product of (i) a polyelectrolyte monomer and (ii) a biological agent recognition element-substituted polyelectrolyte monomer is also provided.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: May 18, 2004
    Assignee: The Regents of the University of California
    Inventor: Liaohai Chen
  • Patent number: 6737280
    Abstract: A class of asymmetric monobenzoxanthene compounds useful as fluorescent dyes are disclosed having structure (I) wherein Y1 and Y2 are individually hydroxyl, amino, imminium, or oxygen, R1-R8 are hydrogen, fluorine, chlorine, alkyl, alkene, alkyne, sulfonate, amino, amido, nitrile, alkoxy, linking group, and combinatios thereof, and R9 is acetylene, alkane, alkene, cyano, substituted phenyl, and combinations thereof. The invention further includes novel intermediate compounds useful for the synthesis of asymmetric benzoxanthene compounds having general structure (II) where substituents R3-R7 correspond to like-referenced substituents in the structure of described above, and Y2 is hydroxyl or amine. In another aspect, the invention includes methods for synthesizing the above dye compounds and intermediates. In yet another aspect, the present invention includes reagents labeled with the asymmetric benzoxanthene dye compounds, including deoxynucleotides, dideoxynucleotides, phosphoramidites, and polynucleotides.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: May 18, 2004
    Assignee: Karl-Heinz Drexhage
    Inventors: Karl-Heinz Drexhage, Jutta Arden-Jacob, Norbert Kemnitzer
  • Patent number: 6737244
    Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Patent number: 6727071
    Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is microplate having cells in a micropaterned array of locations.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: April 27, 2004
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano
  • Patent number: 6723567
    Abstract: The present invention relates to a method for the determination of non-, anti-, or pro-apoptotic and necrotic conditions of cells, newly designed vectors coding for marker proteins, cell lines transfected with such vector, and a method to assay the non-, pro- or anti-apoptotic or necrotic activity of test compounds.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: April 20, 2004
    Assignee: Aponetics Ltd.
    Inventors: Thomas Harr, Alessandro Strebel, Peter Erb, Sinuhe Hahn
  • Patent number: 6720192
    Abstract: A method for assaying an analyte in a sample. The method comprising the steps of a) contacting the sample with material comprising a receptor which is present in a liposome and which liposome comprises a detectable functionality, said contact occurring under conditions resulting in binding of the receptor to analyte if present before or concomitant with step b, wherein step b) consists of contacting the sample with an immobilised ligand for the receptor said contact occurring under conditions resulting in binding of the receptor to the ligand, with steps a and b being followed by c) separating the resulting immobilised ligand-receptor fraction and the receptor fraction present in solution and d) assaying the detectable functionality of the receptor in a fraction from step c) in a manner known per se for its detection.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: April 13, 2004
    Assignee: Merska B.V.
    Inventors: Gerhard Theodoor Viel, Kornelis Ensing
  • Patent number: 6716640
    Abstract: The invention concerns the stabilization and amplification of electrochemiluminescence signals in detection methods.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: April 6, 2004
    Assignee: Roche Diagnostics GmbH
    Inventors: Gabriele Punzmann, Martin Egger, Hans-Peter Josel
  • Patent number: 6706490
    Abstract: A predictive test for rheumatoid arthritis comprises the detection of antibodies to collagen in a biological sample from a patient by contacting the biological sample with an antigen comprising the CB10 peptide of mammalian type II collagen, or an antibody-binding fragment or variant thereof, for a time and under conditions for an antibody-antigen complex to form, and detecting the antibody-antigen complex, for example by immunoassay. A diagnostic test kit is also disclosed.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: March 16, 2004
    Assignees: Montech Medical Developments Pty. Ltd., Rondole Pty. Ltd.
    Inventors: Andrew Cook, Merrill Rowley, Ian Mackay
  • Patent number: 6703248
    Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 &mgr;m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: March 9, 2004
    Assignee: Dade Behring Marburg GmbH
    Inventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
  • Patent number: 6696304
    Abstract: A process, a test kit, calibration standards, and the method of preparing such standards as useful for the qualitative and/or quantitative determination of total solid phase- or microparticle-immobilized, amine-containing reactants such as proteins is provided. The operating principle of the invention is distinct from a classical immunoassay based on antibody-antigen immune interaction or from standard calorimetric proteins assays of soluble proteins and allows the detection of as low as attogram (10−18 gm) levels of total analyte per microparticle.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: February 24, 2004
    Assignee: Luminex Corporation
    Inventor: Travis Parker Davies
  • Patent number: 6692975
    Abstract: Compositions are disclosed comprising (a) a metal chelate wherein the metal is selected from the group consisting of europium, terbium, dysprosium, samarium osmium and ruthenium in at least a hexacoordinated state and (b) a compound having a double bond substituted with two aryl groups, an oxygen atom and an atom selected from the group consisting of oxygen, sulfur and nitrogen wherein one of the aryl groups is electron donating with respect to the other. Such composition is preferably incorporated in a latex particulate material. Methods and kits are also disclosed for determining an analyte in a medium suspected of containing the analyte. The methods and kits employ as one component a composition as described above.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: February 17, 2004
    Assignee: Dade Behring Marburg GmbH
    Inventors: Sharat Singh, Edwin F. Ullman
  • Patent number: 6689568
    Abstract: A method of evaluating for the presence of a polypeptide in an analyte, using an addressable array of capture agents linked to a substrate. The analyte is exposed to the array and a set of fixed capture agents, such that the target molecules will bind to the array by means of the capture agents. After the target molecule has bound to the capture agents, it is modified using a label. The label does not interact or mark the capture agent. Kits using such arrays are further provided.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: February 10, 2004
    Assignee: Agilent Technologies, Inc.
    Inventor: Joel Myerson
  • Patent number: 6686209
    Abstract: In this disclosure, novel caanabinol-based tracers suitable for use in immunoassays that detect cannabinoids in a biological sample are disclosed. These cannabinol-based tracers are particularly useful in a continuous flow displacement immunoassay. The disclosure also describes the processes for synthesizing the novel tracers, and the application of these tracers in fluorescence immunoassays for detecting and quantifying cannabinoids in biological samples.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: February 3, 2004
    Assignee: Lifepoint, Inc.
    Inventors: Guohong Wang, Thomas Foley, Connie Chang, Greg Liang, Albert Avila
  • Patent number: 6677164
    Abstract: The present invention provides biologically active linear polypeptides that possess a plurality of biologically active groups, methods employing such peptides to target molecules to cells, and methods employing such peptides for inhibiting the binding of cells to each other.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: January 13, 2004
    Assignee: Novartis AG
    Inventors: Gebhard Thoma, Rudolf Duthaler, Beat Ernst, John Louis Magnani, John Tinsman Patton, Jr.
  • Patent number: 6670193
    Abstract: The present invention provides fluorescent nucleoside analogs which comprise a fluorescent cyclic compound joined to a carbon of a sugar molecule such as pentose, hexose, ribose or deoxyribose or analogs thereof in either an &agr; or &bgr; configuration. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, the subject compounds are useful in any technique which uses labeled oligonucleotides for detection. Non-fluorescent spacer molecules in which a cyclohexane, cyclohexene, decalin, or benzene is joined to a carbon of a sugar moiety such as pentose, hexose, ribose or deoxyribose are also provided. Also provided are the 5′ dimethoxytrityl-3′-O-phosphoramidite derivatives, suitable for incorporation into oligonucleotides by automated synthesizers.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: December 30, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Eric T. Kool
  • Patent number: 6667179
    Abstract: The invention provides methods and compositions for detecting binding or unbinding of a molecule to a substrate. The molecule comprises a luminophore and the substrate comprises a semiconductor which acts as a luminescence quencher to provide distance-dependent quenching of the luminophore. Binding or unbinding of the molecule, which may be covalent or noncovalent, is detected as a decrease or increase, respectively, of the detectable luminescence of the luminophore.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: December 23, 2003
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Paul R. Selvin
  • Patent number: 6664071
    Abstract: A device for the detection of electromagnetic radiation, wherein the device has (i) a photoactive layer of a semiconductor having a band gap of greater than 2.5 eV, (ii) a dye applied to the semiconductor, and (iii) a charge transport layer comprising a hole conductor material, where the hole conductor material is preferably solid and amorphous.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: December 16, 2003
    Assignee: Nanogen Recognomics GmbH
    Inventors: Norbert Windhab, Hans-Ulrich Hoppe, Donald Lupo
  • Patent number: 6660486
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: December 9, 2003
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Patent number: 6656696
    Abstract: This invention relates to methods and compositions for monitoring the interaction of binding partners as a function of the addition or subtraction of a phosphate group to or from one of the binding partners by a protein kinase or phosphatase.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: December 2, 2003
    Assignee: Cyclacel
    Inventors: Roger K. Craig, John Colyer
  • Patent number: 6653066
    Abstract: Disclosed is a device and method of use for detecting polyvalent analytes such as antibody to the AIDS virus, utilizing an inverse sandwich method. The test device comprises a first substance having an epitope, bound to a label and capable of moving within the test device. The test device further comprises a second substance immobilized to the test device and spatially separated from the first substance. The second substance has an epitope substantially similar to the epitope of the first substance. Upon application to the test device, the polyvalent analyte binds to the first substance and moves within the test device to the location of the second substance with both polyvalent analyte and first substance are immobilized at location of the second substance. Polyvalent analyte is detected by the presence of the label at the location of the second substance. Also disclosed is a control substance for use with the device that can be used to determine completion of the test and viability of the device.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 25, 2003
    Assignee: Trinity Biotech
    Inventor: Siegfried R. Krutzik
  • Patent number: 6649418
    Abstract: The present invention provides internally calibrated competitive assays for use on a solid support. Additionally, the invention provides a method of using such assays.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: November 18, 2003
    Assignee: Silver Lake Research Corporation
    Inventor: Mark S. Geisberg
  • Patent number: 6645724
    Abstract: The horseshoe crab, Carcinoscorpius rotundicauda Factor C cDNA (CrFC21) has been cloned into a shuttle baculoviral vector and another vector suitable for expression in insect cells. The recombinant baculoviral DNA was then transfected into the insect cells for expression of recombinant Factor C. Recombinant Factor C was found to be immunoreactive and is capable of binding both free and bound/immobilized lipid A. It is enzymatically active when triggered by LPS. The rFC is probably of the two-chain form, being cleaved into the heavy and light chains after activation by Gram negative bacterial endotoxin. As low as 0.01 pg (0.001 ng/ml) of LPS was detectable by the rFC, thus, indicating its potentials as a novel generation of “limulus amoebocyte lysate.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: November 11, 2003
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 6635434
    Abstract: A hapten-polymer carrier complex was found to be useful for immunoassay purposes, specifically ELISAs, for the detection of pesticides and their degradation products in hydrosoil and ground water. The degradation products of Casoron G® (also known as dichlorobenzonitrile and dichlorbenil) and Prefix® (also known as chlorthiamid and dichlorobenzthiamide) are analytes detected with high specificity and sensitivity, particularly the degradation product BAM (2,6-dichlorobenzamide). The polymer carrier complex is bound to the hapten via a linker unit, strategically positioned meta to the amide or amide derivative of BAM.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: October 21, 2003
    Assignee: Exiqon A/S
    Inventors: Mogens Havsteen Jakobsen, Leif Bruun, Brian Pedersen
  • Patent number: 6632624
    Abstract: The invention pertains to an immunoassay, and a kit for said assay, in which at least one monoclonal antibody or polyclonal antibody specifically binds to an epitope corresponding to amino acids 145 to 234 of human chromogranin A.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: October 14, 2003
    Assignee: CIS bio International
    Inventors: François Degorce, Laurent Bellanger, Dominique Aunis
  • Patent number: 6630311
    Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: October 7, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Dennis E. Epps, Charles K. Marschke
  • Patent number: 6630355
    Abstract: A magnetic focusing immunosensor for the detection of pathogens comprising a laser, an exciting fiber and a collecting fiber, a fiber optic magnetic probe in communication with the collecting and exciting fibers and means for detecting, collecting and measuring fluorescent signals in communication with the collecting fiber. The probe and the collecting and exciting fibers are configured to focus paramagnetic microspheres attached to antigen/antibody/optically labeled complexes in a predetermined pattern in the field of view of the collecting fiber while blocking background interference.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: October 7, 2003
    Assignees: The Board of Governors for Higher Education State of Rhode Island, Providence Plantation
    Inventors: Philip Pivarnik, He Cao, Stephen V. Letcher, A. Garth Rand
  • Patent number: 6630307
    Abstract: The use of semiconductor nanocrystals as detectable labels in various chemical and biological applications is disclosed. The methods find use for detecting a single analyte, as well as multiple analytes by using more than one semiconductor nanocrystal as a detectable label, each of which emits at a distinct wavelength.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: October 7, 2003
    Assignee: Quantum Dot Corporation
    Inventors: Marcel P. Bruchez, R. Hugh Daniels, Stephen A. Empedocles, Vince E. Phillips, Edith Y. Wong, Donald A. Zehnder
  • Patent number: 6630570
    Abstract: The invention relates to compounds for tumor diagnosis that consist of conjugates of dyes with short-chain peptides, which are derived from vaso-active intestinal peptide, somatostatin or neurotensin, the use of these compounds as optical dignostic agents, and diagnostic agents that contain these compounds.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: October 7, 2003
    Assignee: Insitut für Diagnostikforschung GmbH
    Inventors: Kai Licha, Andreas Becker, Wolfhard Semmler, Bertram Wiedenmann, Carsten Hessenius, Rudolf Volkmer-Engert, Jens Schneider-Mergner
  • Patent number: 6623981
    Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: September 23, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey T. Billheimer, Dietmar A. Seiffert, Leah A. Breth, Timothy C. Burn, Ira B. Dicker, Henry J. George, Gregory F. Hollis, Jeannine M. Hollis, Jennifer E. Kochie, Karyn T. O'Neil
  • Patent number: 6620591
    Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: September 16, 2003
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor
  • Patent number: 6613535
    Abstract: This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: September 2, 2003
    Assignee: Becton, Dickinson andCompany
    Inventors: Joachim Albrecht, Frank Hulstaert, Rosette Becker